rank,company,total_score,fit_score,urgency_score,access_score,trial_count,best_fit_trial_title,best_fit_trial_status,best_fit_trial_phases,best_fit_trial_last_update,best_urgency_trial_title,best_urgency_trial_status,best_urgency_trial_phases,best_urgency_trial_last_update,recent_job_hits,recent_job_total,job_hit_examples,fit_reason,urgency_reason,urgency_source,access_reason,bonus_recent_trial,bonus_multi_trial,trigger_summary,evidence_links,target_roles,job_hit_keywords,job_hit_titles
1,AstraZeneca,9.10,3.0,3.0,2.0,5,"A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.",RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-02-10,"A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.",RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-02-10,0,,,trial title indicates T-cell engager / T-cell engaging / T-cell redirecting,"trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,company on watchlist / ATS known,0.5,0.6,"trial_candidate: A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. | trial_candidate: A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | trial_candidate: Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors",https://clinicaltrials.gov/study/NCT06542250 ; https://clinicaltrials.gov/study/NCT05877599 ; https://clinicaltrials.gov/study/NCT06218914 ; https://clinicaltrials.gov/study/NCT07215585 ; https://clinicaltrials.gov/study/NCT04594642 ; https://clinicaltrials.gov/study/NCT06530849,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",,
2,Pfizer,9.10,3.0,3.0,2.0,5,"A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy",RECRUITING,"[""PHASE3""]",2026-02-03,A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma,RECRUITING,"[""PHASE1""]",2026-01-26,0,,,trial title contains known T-cell engager molecule,trial status RECRUITING and phase in ['PHASE1'],trial,company on watchlist / ATS known,0.5,0.6,"trial_candidate: A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy | trial_candidate: MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | trial_candidate: A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments",https://clinicaltrials.gov/study/NCT05623020 ; https://clinicaltrials.gov/study/NCT06152575 ; https://clinicaltrials.gov/study/NCT05020236 ; https://clinicaltrials.gov/study/NCT05675449 ; https://clinicaltrials.gov/study/NCT06421675,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
3,Regeneron Pharmaceuticals,8.10,3.0,3.0,1.0,17,A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma,RECRUITING,"[""PHASE3""]",2026-02-06,Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma,RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-02-11,0,,,trial title contains known T-cell engager molecule,"trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.5,0.6,trial_candidate: Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma | trial_candidate: A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma | trial_candidate: A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma,https://clinicaltrials.gov/study/NCT03761108 ; https://clinicaltrials.gov/study/NCT06230224 ; https://clinicaltrials.gov/study/NCT06149286 ; https://clinicaltrials.gov/study/NCT02651662 ; https://clinicaltrials.gov/study/NCT05730036 ; https://clinicaltrials.gov/study/NCT06932562 ; https://clinicaltrials.gov/study/NCT05137054 ; https://clinicaltrials.gov/study/NCT06787612,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
4,"Janssen Research & Development, LLC",8.10,3.0,3.0,1.0,9,A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma,ACTIVE_NOT_RECRUITING,"[""PHASE2""]",2026-01-27,A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma,ACTIVE_NOT_RECRUITING,"[""PHASE2""]",2026-01-27,0,,,trial title contains known T-cell engager molecule,trial status ACTIVE_NOT_RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.5,0.6,trial_candidate: A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | trial_candidate: A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel | trial_candidate: A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants,https://clinicaltrials.gov/study/NCT04557098 ; https://clinicaltrials.gov/study/NCT07149857 ; https://clinicaltrials.gov/study/NCT05022849 ; https://clinicaltrials.gov/study/NCT04634552 ; https://clinicaltrials.gov/study/NCT06095089 ; https://clinicaltrials.gov/study/NCT03399799 ; https://clinicaltrials.gov/study/NCT03145181 ; https://clinicaltrials.gov/study/NCT07029776,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
5,Amgen,8.10,3.0,3.0,1.0,6,Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors,RECRUITING,"[""PHASE1"", ""PHASE2""]",2025-10-09,Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer,RECRUITING,"[""PHASE1""]",2026-01-08,0,,,trial title indicates T-cell engager / T-cell engaging / T-cell redirecting,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.6,"trial_candidate: Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | trial_candidate: First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) | trial_candidate: Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)",https://clinicaltrials.gov/study/NCT04221542 ; https://clinicaltrials.gov/study/NCT05361395 ; https://clinicaltrials.gov/study/NCT03319940 ; https://clinicaltrials.gov/study/NCT06502977 ; https://clinicaltrials.gov/study/NCT06814496 ; https://clinicaltrials.gov/study/NCT06816394,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
6,AbbVie,7.95,3.0,3.0,1.0,4,"Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia",RECRUITING,"[""PHASE1""]",2026-02-10,"Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia",RECRUITING,"[""PHASE1""]",2026-02-10,0,,,trial title contains known T-cell engager molecule,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.44999999999999996,"trial_collaborator: Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia | trial_candidate: A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma | trial_collaborator: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome",https://clinicaltrials.gov/study/NCT04872790 ; https://clinicaltrials.gov/study/NCT03933735 ; https://clinicaltrials.gov/study/NCT04623541 ; https://clinicaltrials.gov/study/NCT07097363 ; https://clinicaltrials.gov/study/NCT06672705,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",,
7,"CARsgen Therapeutics Co., Ltd.",7.80,3.0,3.0,1.0,3,"A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus",RECRUITING,"[""EARLY_PHASE1""]",2026-01-14,"Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection",ACTIVE_NOT_RECRUITING,"[""PHASE1"", ""PHASE2""]",2025-06-05,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,"trial status ACTIVE_NOT_RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.5,0.3,"trial_collaborator: A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus | trial_candidate: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection | trial_candidate: Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL",https://clinicaltrials.gov/study/NCT07339332 ; https://clinicaltrials.gov/study/NCT04581473 ; https://clinicaltrials.gov/study/NCT06333509,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
8,"Chongqing Precision Biotech Co., Ltd",7.80,3.0,3.0,1.0,3,Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors,RECRUITING,"[""PHASE1""]",2026-01-23,Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors,RECRUITING,"[""PHASE1""]",2026-01-23,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.3,trial_collaborator: Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors | trial_candidate: Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN | trial_candidate: Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors,https://clinicaltrials.gov/study/NCT06821048 ; https://clinicaltrials.gov/study/NCT06690827 ; https://clinicaltrials.gov/study/NCT06126406,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
9,Genmab,7.80,3.0,3.0,1.0,3,Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome,RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-02-03,Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome,RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-02-03,0,,,trial title contains known T-cell engager molecule,"trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.5,0.3,trial_candidate: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome | trial_candidate: GEN1047 for Solid Tumors - First in Human (FIH) Trial | trial_collaborator: Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders,https://clinicaltrials.gov/study/NCT04623541 ; https://clinicaltrials.gov/study/NCT05180474 ; https://clinicaltrials.gov/study/NCT06672705,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",,
10,Cullinan Therapeutics Inc.,7.80,3.0,3.0,1.0,3,"A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease",RECRUITING,"[""PHASE1""]",2025-11-19,CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS),RECRUITING,"[""PHASE1""]",2026-01-16,0,,,trial title indicates T-cell engager / T-cell engaging / T-cell redirecting,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.3,"trial_candidate: CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | trial_candidate: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease | trial_candidate: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis",https://clinicaltrials.gov/study/NCT05143996 ; https://clinicaltrials.gov/study/NCT07041099 ; https://clinicaltrials.gov/study/NCT06994143,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
11,"TScan Therapeutics, Inc.",7.80,3.0,3.0,1.0,3,A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors,ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2025-11-17,A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors,ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2025-11-17,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status ACTIVE_NOT_RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.3,"trial_candidate: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | trial_candidate: A Long Term Follow-up Study of TScan TCR-T Products | trial_candidate: A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation",https://clinicaltrials.gov/study/NCT05973487 ; https://clinicaltrials.gov/study/NCT06976736 ; https://clinicaltrials.gov/study/NCT05473910,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
12,Allorunning Therapeutics,7.65,3.0,3.0,1.0,2,A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies,NOT_YET_RECRUITING,"[""PHASE1""]",2026-01-05,A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas,NOT_YET_RECRUITING,"[""PHASE1""]",2026-01-06,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status NOT_YET_RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.15,trial_collaborator: A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas | trial_collaborator: A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies,https://clinicaltrials.gov/study/NCT07316920 ; https://clinicaltrials.gov/study/NCT07316907,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
13,"Hebei Taihe Chunyu Biotechnology Co., Ltd",7.65,3.0,3.0,1.0,2,"Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma",NOT_YET_RECRUITING,"[""PHASE1"", ""PHASE2""]",2025-12-02,"Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma",NOT_YET_RECRUITING,"[""PHASE1"", ""PHASE2""]",2025-12-02,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,"trial status NOT_YET_RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.5,0.15,"trial_collaborator: Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma | trial_collaborator: The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors",https://clinicaltrials.gov/study/NCT07259070 ; https://clinicaltrials.gov/study/NCT06911710,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
14,"Kite, A Gilead Company",7.65,3.0,3.0,1.0,2,GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma,RECRUITING,"[""PHASE1""]",2025-12-29,GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma,RECRUITING,"[""PHASE1""]",2025-12-29,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.15,trial_collaborator: GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma | trial_collaborator: Axi-cel in CNS Lymphoma,https://clinicaltrials.gov/study/NCT05650749 ; https://clinicaltrials.gov/study/NCT04608487,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
15,Miltenyi Biomedicine GmbH,7.65,3.0,3.0,1.0,2,CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia,RECRUITING,"[""PHASE1""]",2026-01-22,CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia,RECRUITING,"[""PHASE1""]",2026-01-22,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.15,trial_collaborator: CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia | trial_candidate: MB-dNPM1-TCR.1 in Relapsed/Refractory AML,https://clinicaltrials.gov/study/NCT07361029 ; https://clinicaltrials.gov/study/NCT06424340,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",,
16,"PersonGen BioTherapeutics (Suzhou) Co., Ltd.",7.65,3.0,3.0,1.0,2,Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia,RECRUITING,"[""PHASE1""]",2022-07-06,Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia,RECRUITING,"[""PHASE1""]",2022-07-06,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.15,trial_candidate: Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies | trial_collaborator: Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia,https://clinicaltrials.gov/study/NCT07338604 ; https://clinicaltrials.gov/study/NCT05445011,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
17,"Corregene Biotechnology Co., Ltd",7.65,3.0,3.0,1.0,2,KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors,ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2026-01-30,KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors,ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2026-01-30,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status ACTIVE_NOT_RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.15,trial_candidate: KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors | trial_candidate: CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers,https://clinicaltrials.gov/study/NCT06767046 ; https://clinicaltrials.gov/study/NCT06358053,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
18,Beam Therapeutics Inc.,7.50,3.0,3.0,1.0,1,Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma,RECRUITING,"[""PHASE1""]",2025-12-26,Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma,RECRUITING,"[""PHASE1""]",2025-12-26,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.0,trial_collaborator: Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma,https://clinicaltrials.gov/study/NCT06934382,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
19,Gilead Sciences,7.50,3.0,3.0,1.0,1,GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma,RECRUITING,"[""PHASE1""]",2025-12-29,GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma,RECRUITING,"[""PHASE1""]",2025-12-29,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.0,trial_collaborator: GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma,https://clinicaltrials.gov/study/NCT05650749,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
20,Tcelltech Inc.,7.50,3.0,3.0,1.0,1,Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors,RECRUITING,"[""PHASE1""]",2025-11-17,Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors,RECRUITING,"[""PHASE1""]",2025-11-17,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.0,trial_candidate: Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT07231081,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
21,T-MAXIMUM Pharmaceutical Inc,7.50,3.0,3.0,1.0,1,The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma,NOT_YET_RECRUITING,"[""PHASE2""]",2026-02-10,The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma,NOT_YET_RECRUITING,"[""PHASE2""]",2026-02-10,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status NOT_YET_RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.5,0.0,trial_candidate: The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma,https://clinicaltrials.gov/study/NCT07386002,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
22,"Genentech, Inc.",7.50,3.0,3.0,1.0,1,Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma,ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2026-01-08,Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma,ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2026-01-08,0,,,trial title contains known T-cell engager molecule,trial status ACTIVE_NOT_RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.0,trial_collaborator: Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma,https://clinicaltrials.gov/study/NCT05464329,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",,
23,"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",7.50,3.0,3.0,1.0,1,Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma,RECRUITING,"[""PHASE2""]",2026-02-10,Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma,RECRUITING,"[""PHASE2""]",2026-02-10,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.5,0.0,trial_candidate: Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma,https://clinicaltrials.gov/study/NCT06297226,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
24,Janssen Pharmaceuticals,7.50,3.0,3.0,1.0,1,Teclistamab-Daratumumab in AL Amyloidosis,RECRUITING,"[""PHASE2""]",2025-11-19,Teclistamab-Daratumumab in AL Amyloidosis,RECRUITING,"[""PHASE2""]",2025-11-19,0,,,trial title contains known T-cell engager molecule,trial status RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.5,0.0,trial_collaborator: Teclistamab-Daratumumab in AL Amyloidosis,https://clinicaltrials.gov/study/NCT07110844,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",,
25,Janssen Pharmaceutical K.K.,7.50,3.0,3.0,1.0,1,A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma,ACTIVE_NOT_RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-01-16,A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma,ACTIVE_NOT_RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-01-16,0,,,trial title contains known T-cell engager molecule,"trial status ACTIVE_NOT_RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.5,0.0,trial_candidate: A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma,https://clinicaltrials.gov/study/NCT04696809,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",,
26,"C4 Therapeutics, Inc.",7.50,3.0,3.0,1.0,1,A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects,RECRUITING,"[""PHASE1""]",2026-01-29,A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects,RECRUITING,"[""PHASE1""]",2026-01-29,0,,,trial title contains known T-cell engager molecule,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.0,trial_candidate: A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects,https://clinicaltrials.gov/study/NCT07280013,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",,
27,"Shanghai Ruiliyuan Biotechnology Co., Ltd.",7.50,3.0,3.0,1.0,1,HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors,RECRUITING,"[""PHASE1""]",2025-12-02,HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors,RECRUITING,"[""PHASE1""]",2025-12-02,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.0,trial_candidate: HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors,https://clinicaltrials.gov/study/NCT06515314,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
28,SCG Cell Therapy Pte. Ltd.,7.30,3.0,3.0,1.0,3,A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related,RECRUITING,"[""PHASE1""]",2024-09-27,A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma,RECRUITING,"[""PHASE1"", ""PHASE2""]",2025-02-18,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,"trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.0,0.3,trial_candidate: A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma | trial_candidate: A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related | trial_candidate: Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma,https://clinicaltrials.gov/study/NCT05417932 ; https://clinicaltrials.gov/study/NCT06617000 ; https://clinicaltrials.gov/study/NCT06505551,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
29,Lion TCR Pte. Ltd.,7.30,3.0,3.0,1.0,3,Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma,RECRUITING,"[""PHASE1""]",2025-05-08,Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma,RECRUITING,"[""PHASE1""]",2025-05-08,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.0,0.3,trial_candidate: Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma | trial_candidate: Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC | trial_candidate: Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV),https://clinicaltrials.gov/study/NCT06961617 ; https://clinicaltrials.gov/study/NCT05195294 ; https://clinicaltrials.gov/study/NCT04745403,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
30,"Iovance Biotherapeutics, Inc.",7.30,3.0,3.0,1.0,3,E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers,RECRUITING,"[""PHASE2""]",2025-03-30,E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers,RECRUITING,"[""PHASE1"", ""PHASE2""]",2025-08-19,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,"trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.0,0.3,"trial_collaborator: E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | trial_collaborator: E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | trial_collaborator: KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer",https://clinicaltrials.gov/study/NCT05639972 ; https://clinicaltrials.gov/study/NCT05686226 ; https://clinicaltrials.gov/study/NCT05483491,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
31,"Beijing Immunochina Medical Science & Technology Co., Ltd.",7.15,3.0,3.0,1.0,2,Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer,RECRUITING,"[""PHASE1""]",2024-12-05,Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer,RECRUITING,"[""PHASE1""]",2024-12-05,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.0,0.15,trial_candidate: Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer | trial_candidate: Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients,https://clinicaltrials.gov/study/NCT06718738 ; https://clinicaltrials.gov/study/NCT04440436,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
32,"Shanghai Ming Ju Biotechnology Co., Ltd.",7.15,3.0,3.0,1.0,2,MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors,RECRUITING,"[""PHASE1""]",2023-12-14,Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis,RECRUITING,"[""PHASE1""]",2024-08-15,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.0,0.15,trial_collaborator: Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis | trial_collaborator: MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT06414135 ; https://clinicaltrials.gov/study/NCT06170294,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
33,"Hebei Senlang Biotechnology Inc., Ltd.",7.15,3.0,3.0,1.0,2,Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases,NOT_YET_RECRUITING,"[""PHASE1"", ""PHASE2""]",2025-09-08,Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases,NOT_YET_RECRUITING,"[""PHASE1"", ""PHASE2""]",2025-09-08,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,"trial status NOT_YET_RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.0,0.15,trial_candidate: Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases | trial_candidate: CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study,https://clinicaltrials.gov/study/NCT07161193 ; https://clinicaltrials.gov/study/NCT06136364,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
34,"Guangzhou FineImmune Biotechnology Co., LTD.",7.15,3.0,3.0,1.0,2,"An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors",RECRUITING,"[""PHASE1""]",2025-09-03,"An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors",RECRUITING,"[""PHASE1""]",2025-09-03,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.0,0.15,"trial_candidate: An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors | trial_candidate: Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors",https://clinicaltrials.gov/study/NCT06942143 ; https://clinicaltrials.gov/study/NCT03891706,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
35,Cabaletta Bio,7.00,3.0,3.0,1.0,1,"RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis",RECRUITING,"[""PHASE1"", ""PHASE2""]",2025-09-29,"RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis",RECRUITING,"[""PHASE1"", ""PHASE2""]",2025-09-29,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,"trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.0,0.0,"trial_candidate: RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis",https://clinicaltrials.gov/study/NCT06328777,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
36,Celgene Corporation,7.00,3.0,3.0,1.0,1,Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma,RECRUITING,"[""PHASE1""]",2025-08-13,Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma,RECRUITING,"[""PHASE1""]",2025-08-13,0,,,trial title contains known T-cell engager molecule,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.0,0.0,trial_collaborator: Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma,https://clinicaltrials.gov/study/NCT06348108,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",,
37,Hoffmann-La Roche,7.00,3.0,3.0,1.0,1,"A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).",NOT_YET_RECRUITING,"[""PHASE2""]",2025-09-24,"A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).",NOT_YET_RECRUITING,"[""PHASE2""]",2025-09-24,0,,,trial title contains known T-cell engager molecule,trial status NOT_YET_RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.0,0.0,"trial_collaborator: A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).",https://clinicaltrials.gov/study/NCT07191249,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",,
38,Chiome Bioscience Inc.,7.00,3.0,3.0,1.0,1,"A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.",RECRUITING,"[""PHASE1""]",2025-06-12,"A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.",RECRUITING,"[""PHASE1""]",2025-06-12,0,,,trial title indicates T-cell engager / T-cell engaging / T-cell redirecting,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.0,0.0,"trial_candidate: A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.",https://clinicaltrials.gov/study/NCT07016997,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
39,Pharmacyclics LLC.,7.00,3.0,3.0,1.0,1,Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia,RECRUITING,"[""PHASE2""]",2024-05-29,Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia,RECRUITING,"[""PHASE2""]",2024-05-29,0,,,trial title contains known T-cell engager molecule,trial status RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.0,0.0,trial_collaborator: Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT02997761,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",,
40,Celldex Therapeutics,7.00,3.0,3.0,1.0,1,Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T),ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2024-11-25,Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T),ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2024-11-25,0,,,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status ACTIVE_NOT_RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.0,0.0,trial_collaborator: Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T),https://clinicaltrials.gov/study/NCT05349890,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",,
